A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA

Orthopedics

Volumn 34, Issue 4, 2011, Pages

  Zeng, Yi ^a   Lai, Oujie ^a   Shen, Bin ^a   Yang, Jing ^a   Zhou, Zongke ^a   Kang, Pengde ^a   Pei, Fuxing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; AVASCULAR NECROSIS; BONE ATROPHY; BONE DENSITY; BONE TURNOVER; CHRONIC DRUG ADMINISTRATION; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK FRACTURE; FOLLOW UP; HIP DYSPLASIA; HIP OSTEOARTHRITIS; HIP RADIOGRAPHY; HUMAN; META ANALYSIS; OSTEOLYSIS; OUTCOME ASSESSMENT; PERIPROSTHETIC FRACTURE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS;

ALENDRONATE; ARTHROPLASTY, REPLACEMENT, HIP; BONE CEMENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CEMENTATION; HUMANS; OSTEOLYSIS; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79955009412     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20110228-09     Document Type: Review

References (24)

1. Chang RW, Pellisier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA. 1996; 275(11):858-865. (Pubitemid 26087223)
2. McCarthy CK, Steinberg GG, Agren M, Leahey D, Wyman E, Baran DT. Quantifying bone loss from the proximal femur after total hip arthroplasty. J Bone Joint Surg Br. 1991; 73(5):774-778.
3. Kiratli BJ, Checovich MM, McBeath AA, Wilson MA, Heiner JP. Measurement of bone mineral density by dual-energy x-ray absorptiometry in patients with the Wisconsin hip, an uncemented femoral stem. J Arthroplasty. 1996; 11(2):184-193. (Pubitemid 26070697)
4. Kröger H, Venesmaa P, Jurvelin J, Miettinen H, Suomalainen O, Alhava E. Bone density at the proximal femur after total hop arthroplasty. Clin Orthop Relat Res. 1998; (352):66-74. (Pubitemid 28326285)
5. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM. Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry - a 3-year follow-up study. J Bone Miner Res. 2001; 16 (6):1056-1061. (Pubitemid 32467149)
6. Brodner W, Bitzan P, Lomoschitz F, et al. Changes in bone mineral density in the proximal femur after cementless total hip arthroplasty. A five-year longitudinal study. J Bone Joint Surg Br. 2004; 86(1):20-26. (Pubitemid 38128699)
7. Braun A, Papp J, Reiter A. The periprosthetic bone remodeling process - signs of vital bone reaction. Int Orthop. 2003; 27(Suppl 1):S7-10.
8. Kobayashi S, Saito N, Horiuchi H, Iorio R, Takaoka K. Poor bone quality or hip structure as risk factors affecting survival of totalhip arthroplasty. Lancet. 2000; 355(9214):1499-1504. (Pubitemid 30237356)
9. Woolf AD, Akesson K. Preventing fractures in elderly people. BMJ. 2003; 327(7406):89-95. (Pubitemid 36836461)
10. Bohic S, Rey C, Legrand A, et al. Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment. Bone. 2000; 26(4):341-348. (Pubitemid 30136123)
11. Hilding M, Aspenberg P. Local preoperative treatment with a bisphosphonate improves the fixation of total knee prosthesis: a randomized. double-blind radiostereometric study of 50 patients. Acta Orthop. 2007; 78(6):795-799.
12. Shanbhag AS. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg. 2006; 14 (4):215-225. (Pubitemid 44916666)
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17(1):1-12. (Pubitemid 26120810)
14. Gruen TA, McNeice GM, Amstutz HC. "Modes of failure" of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979; (141):17-27. (Pubitemid 10233166)
15. Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJ, Kröger HP. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. Scand J Surg. 2010; 99(1):32-37.
16. Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res. 2009; 27(2):183-188.
17. Nishioka T, Yagi S, Mitsuhashi T, et al. Alendronate inhibits periprosthetic bone loss around uncemented femoral components [published online ahead of print April 20, 2007]. J Bone Miner Metab. 2007; 25(3):179-183. (Pubitemid 46643763)
18. Arabmotlagh M, Rittmeister M, Hennigs T. Alendronate prevents femoral periprosthetic bone losss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res. 2004; 24(7):1336-1341. (Pubitemid 44083248)
19. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001; 16(11):2126-2131. (Pubitemid 32995405)
20. Wilkinson JM, Stockley I, Peel NF, et al. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res. 2001; 16(3):556-564. (Pubitemid 32173371)
21. Bobyn JD, Mortimer ES, Glassman AH, Engh CA, Miller JE, Brooks CE. Producing and avoiding stress shielding. Laboratory and clinical observations of noncemented total hip arthroplasty. Clin Orthop Relat Res. 1992; (274):79-96.
22. Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty [published online ahead of print February 15, 2007]. Osteoporos Int. 2007; 18(7):1009-1015. (Pubitemid 46889560)
23. Shetty N, Hamer AJ, Stockley I, Eastell R, Willkinson JM. Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg Br. 2006; 88(10):1309-1315. (Pubitemid 44613145)
24. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271(9):684-689. (Pubitemid 24061703)